Study 30 of 34Retatrutide (LY3437943) literatureLancet (London, England)Top journal2026
Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?
Not reported in abstract.
Where it sits
this study against the rest of the retatrutide (ly3437943) corpus14
Preclinical · this one
7
Observational
0
Open-label
6
Randomised
7
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Retatrutide (LY3437943) corpus
DGLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases.European journal of pharmacology · 2026reviewARetatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.The New England journal of medicine · 2026 · -34.3 events/hour AHI change with 9 mg retatrutide vs -9.9 with placebo in TRIUMPH-1-OSA, difference vs placebo -24.4 (95% CI, -34.1 to -14.7)HumanDUnapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.JAMA · 2026—DUnapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.JAMA · 2026—DRetatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.BMJ (Clinical research ed.) · 2026—AThe First Triple Agonist for Antiobesity: Retatrutide.Cardiology in review · 2024 · Not reported in abstract.review